固酶抑制会增加状GDNF,并防止临床前的帕金森症
Xavier d'Anglemont de Tassigny1,2,3, Alejandro Jiménez-Medina1,2,3, Ivette López-López1
1Institute of Biomedicine of Seville (IBiS), University Hospital "Virgen del Rocío", CSIC, University of Seville, Seville, Spain.
Journal of neurochemistry
|December 12, 2025
概括
布迪拉斯特是一种PDE抑制剂,在帕金森病中增强质细胞系衍生神经营养因子 (GDNF).
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 质细胞系衍生神经营养因子 (GDNF) 显示出对帕金森病 (PD) 治疗的潜力,但结果各不相同.
- 大脑内源性GDNF的产生与循环腺单酸盐 (cAMP) 信号传递有关.
- 提高细胞内cAMP是一种增强GDNF用于PD神经保护的策略.
研究的目的:
- 研究固酶 (PDE) 抑制对增加cAMP和GDNF表达的作用.
- 在PD模型中评估Ibudilast,一种非选择性PDE抑制剂,其在调节GDNF并提供神经保护方面的有效性.
主要方法:
- 选择性PDE抑制体外活体来评估Gdnf mRNA表达.
- 在体内进行系统的Ibudilast注射.
- 使用了长期MPTP小鼠模型的帕金森病.
主要成果:
- 抑制PDE在体内增加了GdnfmRNA的表达.
- 伊布迪拉斯特强烈上调排列性GDNF表达,无论是体外还是体内.
- 在MPTP小鼠模型中,Ibudilast治疗保留了多巴胺能神经元,减少了纤维损失,并减轻了多巴胺耗尽.
结论:
- 伊布迪拉斯特有效地增加了体内内GDNF表达.
- 伊布迪拉斯特在PD的小鼠模型中显示出显著的神经保护作用.
- 伊布迪拉斯特需要进一步研究,作为帕金森病的疾病修饰疗法.
更多相关视频
12:49Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation
Published on: March 21, 2020
8.0K
05:38Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model
Published on: January 7, 2019
18.9K
相关概念视频
01:24Parkinson's Disease: Treatment
940
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
940
01:15Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
2.5K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
2.5K
02:54Protein Kinases and Phosphatases
14.9K
Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
14.9K
01:37Neural Regulation
43.0K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.0K
01:29Drugs Affecting Neurotransmitter Synthesis
2.1K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.1K